These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28931560)

  • 21. Medullary thyroid cancer: molecular factors, management and treatment.
    Pavlidis E; Sapalidis K; Chatzinikolaou F; Kesisoglou I
    Rom J Morphol Embryol; 2020; 61(3):681-686. PubMed ID: 33817709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2).
    Jimenez C; Gagel RF
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S150-7. PubMed ID: 15135800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
    Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
    J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular advances in medullary thyroid cancer diagnostics.
    Hubner RA; Houlston RS
    Clin Chim Acta; 2006 Aug; 370(1-2):2-8. PubMed ID: 16519882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanisms of RET activation in human cancer.
    Santoro M; Melillo RM; Carlomagno F; Fusco A; Vecchio G
    Ann N Y Acad Sci; 2002 Jun; 963():116-21. PubMed ID: 12095936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple endocrine neoplasia type 2.
    Marini F; Falchetti A; Del Monte F; Carbonell Sala S; Tognarini I; Luzi E; Brandi ML
    Orphanet J Rare Dis; 2006 Nov; 1():45. PubMed ID: 17105651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple endocrine neoplasia, the old and the new: a mini review.
    Pasquali D; Di Matteo FM; Renzullo A; Accardo G; Esposito D; Barbato F; Colantuoni V; Circelli L; Conzo G
    G Chir; 2012; 33(11-12):370-3. PubMed ID: 23140918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma.
    Jhiang SM; Fithian L; Weghorst CM; Clark OH; Falko JM; O'Dorisio TM; Mazzaferri EL
    Thyroid; 1996 Apr; 6(2):115-21. PubMed ID: 8733882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
    Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
    Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the RET pathway in thyroid cancer.
    Wells SA; Santoro M
    Clin Cancer Res; 2009 Dec; 15(23):7119-23. PubMed ID: 19934298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic.
    Jindrichová S; Vcelák J; Vlcek P; Neradilová M; Nemec J; Bendlová B
    J Endocrinol; 2004 Nov; 183(2):257-65. PubMed ID: 15531714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
    Kameyama K; Okinaga H; Takami H
    Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
    Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors.
    Wells SA
    Endocr Relat Cancer; 2018 Feb; 25(2):T1-T13. PubMed ID: 29142004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
    Frank-Raue K; Rondot S; Schulze E; Raue F
    Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
    Matrone A; Gambale C; Prete A; Elisei R
    Front Endocrinol (Lausanne); 2022; 13():864253. PubMed ID: 35422765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
    Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R
    Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Multiple endocrine neoplasia type 2].
    Niccoli-Sire P; Conte-Devolx B
    Ann Endocrinol (Paris); 2007 Oct; 68(5):317-24. PubMed ID: 17626779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple endocrine neoplasia type 2.
    Lodish M
    Front Horm Res; 2013; 41():16-29. PubMed ID: 23652668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.